Sfoglia per Autore
First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma.
2004 Cavo M; Zamagni E; Tosi P; Cellini C; Cangini D; Tacchetti P; Testoni N; Tonelli M; de Vivo A; Palareti G; Tura S; Baccarani M.
Thalidomide alone or in combination with dexamethasone in patients with advanced, relapsed or refractory multiple myeloma and renal failure.
2004 TOSI P; ZAMAGNI E; CELLINI C; CANGINI D; TACCHETTI P; TURA S; BACCARANI M.; CAVO M.
Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma.
2005 CAVO M; ZAMAGNI E; TOSI P; TACCHETTI P; CELLINI C; CANGINI D; DE VIVO A; TESTONI N; NICCI C; TERRAGNA C; GRAFONE T; PERRONE G; CECCOLINI M; TURA S; BACCARANI M.; BOLOGNA STUDY.
Neurological toxicity of long-term (>1 yr) thalidomide therapy in patients with multiple myeloma.
2005 TOSI P; ZAMAGNI E; CELLINI C; PLASMATI R; CANGINI D; TACCHETTI P; PERRONE; G; PASTORELLI F; TURA S; BACCARANI M.; CAVO M.
Poor outcome with front-line autologous transplantation in t(4;14) multiple myeloma: low complete remission rate and short duration of remission.
2006 Cavo M; Terragna C; Renzulli M; Zamagni E; Tosi P; Testoni N; Nicci C; Cangini D; Tacchetti P; Grafone T; Cellini C; Ceccolini M; Perrone G; Martinelli G; Baccarani M; Guardigni L.
First-line therapy with thalidomide, dexamethasone and zoledronic acid decreases bone resorption markers in patients with multiple myeloma.
2006 Tosi P; Zamagni E; Cellini C; Parente R; Cangini D; Tacchetti P; Perrone G; Ceccolini M; Boni P; Tura S; Baccarani M; Cavo M.
Osteonecrosis of the jaws in newly diagnosed multiple myeloma patients treatedwith zoledronic acid and thalidomide-dexamethasone.
2006 Tosi P; Zamagni E; Cangini D; Tacchetti P; Di Raimondo F; Catalano L; D'ArcoA; Ronconi S; Cellini C; Offidani M; Perrone G; Ceccolini M; Brioli A; Tura S;Baccarani M; Cavo M.
Complete remission upon bortezomib-dexamethasone therapy in three heavily pretreated multiple myeloma patients relapsing after allogeneic stem cell transplantation.
2006 Tosi P; Zamagni E; Cangini D; Tacchetti P; Perrone G; Ceccolini M; Baccarani M; Cavo M.
Prediction of response to primary therapy with thalidomide-dexamethasone (thal-dex) for newly diagnosed multiple myeloma by gene expression profiling (gep)
2007 Terragna, C.; Renzulli, M.; Remondini, D.; Tagliafico, E.; Roncaglia, E.; Tosi, P.; Zamagni, E.; Tacchetti, P.; Perrone, G.; Ceccolini, M.; Brioli, Am.; Martinelli, G.; Baccarani, M.; Cavo, M.
Neuropathy in multiple myeloma treated with thalidomide: a prospective study.
2007 Plasmati R; Pastorelli F; Cavo M; Petracci E; Zamagni E; Tosi P; Cangini D; Tacchetti P; Salvi F; Bartolomei I; Michelucci R; Tassinari CA.
Prediction of response to primary therapy with thalidomide-dexamethasone (thal-dex) for newly diagnosed multiple myeloma by gene expression profiling (gep)
2007 Terragna C.; Renzulli M.; Remondini D.; Tagliafico E.; Roncaglia E.; Tosi P.; Zamagni E.; Tacchetti P.; Perrone G.; Ceccolini M.; Brioli AM.; Martinelli G.; Baccarani M.; Cavo M.
Gene expression profiling (gep) of myeloma (MM) cells to predict attainment near complete response to primary therapy with thalidomide-dexamethasone (thal-dex) for newly diagnosed MM
2007 C. Terragna; M. Renzulli; D. Remondini; E. Tagliafico; E. Roncaglia; P. Tosi; E. Zamagni; P. Tacchetti; G. Perrone; M. Ceccolini; G. Martinelli; M. Baccarani; M. Cavo
Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study.
2007 Cavo M; Tosi P; Zamagni E; Cellini C; Tacchetti P; Patriarca F; Di Raimondo F; Volpe E; Ronconi S; Cangini D; Narni F; Carubelli A; Masini L; Catalano L; Fiacchini M; de Vivo A; Gozzetti A; Lazzaro A; Tura S; Baccarani M.
A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma.
2007 Zamagni E; Nanni C; Patriarca F; Englaro E; Castellucci P; Geatti O; Tosi P; Tacchetti P; Cangini D; Perrone G; Ceccolini M; Brioli A; Buttignol S; Fanin R; Salizzoni E; Baccarani M; Fanti S; Cavo M.
11C-choline vs. 18F-FDG PET/CT in assessing bone involvement in patients with multiple myeloma.
2007 Nanni C; Zamagni E; Cavo M; Rubello D; Tacchetti P; Pettinato C; Farsad M; Castellucci P; Ambrosini V; Montini GC; Al-Nahhas A; Franchi R; Fanti S.
Evaluation of bone disease in multiple myeloma patients carrying the t(4;14) chromosomal translocation.
2008 Tosi P; Terragna C; Testoni N; Zamagni E; Renzulli M; Tacchetti P; Montanari E; Perrone G; Ceccolini M; Brioli A; Pallotti MC; Tura S; Baccarani M; Cavo M.
Proteasome inhibitors: Bortezomib in multiple myeloma
2008 Cavo M.; Pallotti M.C.; Pantani L.; Petrucci A.; Brioli A.; Terragna C.; Testoni N.; Marzocchi G.; Durante S.; Ceccolini M.; Perrone G.; Tacchetti P.; Zamagni E.; Tosi P.; Baccarani M.
Short-term thalidomide incorporated into double autologous stem-cell transplantation improves outcomes in comparison with double autotransplantation for multiple myeloma.
2009 Cavo M; Di Raimondo F; Zamagni E; Patriarca F; Tacchetti P; Casulli AF; Volpe S; Perrone G; Ledda A; Ceccolini M; Califano C; Bigazzi C; Offidani M; Stefani P; Ballerini F; Fiacchini M; de Vivo A; Brioli A; Tosi P; Baccarani M.
Thalidomide maintenance in multiple myeloma: certainties and controversies.
2009 Cavo M; Pantani L; Tacchetti P; Pallotti MC; Brioli A; Petrucci A; Zamagni E; Tosi P.
The road to cure in multiple myeloma: Incorporation of novel agents into autologous stem cell transplantation
2009 Cavo M.; Zamagni E.; Tacchetti P.; Brioli A.; Pallotti C.; Pantani L.; Ceccolini M.; Petrucci A.; Testoni N.; Terragna C.; Marzocchi G.; Durante S.; Tosi P.; Baccarani M.
| Titolo | Autore(i) | Anno | Periodico | Editore | Tipo | File |
|---|---|---|---|---|---|---|
| First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma. | Cavo M; Zamagni E; Tosi P; Cellini C; Cangini D; Tacchetti P; Testoni N; Tonelli M; de Vivo A; Pa...lareti G; Tura S; Baccarani M. | 2004-01-01 | HAEMATOLOGICA | - | 1.01 Articolo in rivista | - |
| Thalidomide alone or in combination with dexamethasone in patients with advanced, relapsed or refractory multiple myeloma and renal failure. | TOSI P; ZAMAGNI E; CELLINI C; CANGINI D; TACCHETTI P; TURA S; BACCARANI M.; CAVO M. | 2004-01-01 | EUROPEAN JOURNAL OF HAEMATOLOGY | - | 1.01 Articolo in rivista | - |
| Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. | CAVO M; ZAMAGNI E; TOSI P; TACCHETTI P; CELLINI C; CANGINI D; DE VIVO A; TESTONI N; NICCI C; TERR...AGNA C; GRAFONE T; PERRONE G; CECCOLINI M; TURA S; BACCARANI M.; BOLOGNA STUDY. | 2005-01-01 | BLOOD | - | 1.01 Articolo in rivista | - |
| Neurological toxicity of long-term (>1 yr) thalidomide therapy in patients with multiple myeloma. | TOSI P; ZAMAGNI E; CELLINI C; PLASMATI R; CANGINI D; TACCHETTI P; PERRONE; G; PASTORELLI F; TURA ...S; BACCARANI M.; CAVO M. | 2005-01-01 | EUROPEAN JOURNAL OF HAEMATOLOGY | - | 1.01 Articolo in rivista | - |
| Poor outcome with front-line autologous transplantation in t(4;14) multiple myeloma: low complete remission rate and short duration of remission. | Cavo M; Terragna C; Renzulli M; Zamagni E; Tosi P; Testoni N; Nicci C; Cangini D; Tacchetti P; Gr...afone T; Cellini C; Ceccolini M; Perrone G; Martinelli G; Baccarani M; Guardigni L. | 2006-01-01 | JOURNAL OF CLINICAL ONCOLOGY | - | 1.01 Articolo in rivista | - |
| First-line therapy with thalidomide, dexamethasone and zoledronic acid decreases bone resorption markers in patients with multiple myeloma. | Tosi P; Zamagni E; Cellini C; Parente R; Cangini D; Tacchetti P; Perrone G; Ceccolini M; Boni P; ...Tura S; Baccarani M; Cavo M. | 2006-01-01 | EUROPEAN JOURNAL OF HAEMATOLOGY | - | 1.01 Articolo in rivista | - |
| Osteonecrosis of the jaws in newly diagnosed multiple myeloma patients treatedwith zoledronic acid and thalidomide-dexamethasone. | Tosi P; Zamagni E; Cangini D; Tacchetti P; Di Raimondo F; Catalano L; D'ArcoA; Ronconi S; Cellini... C; Offidani M; Perrone G; Ceccolini M; Brioli A; Tura S;Baccarani M; Cavo M. | 2006-01-01 | BLOOD | - | 1.01 Articolo in rivista | - |
| Complete remission upon bortezomib-dexamethasone therapy in three heavily pretreated multiple myeloma patients relapsing after allogeneic stem cell transplantation. | Tosi P; Zamagni E; Cangini D; Tacchetti P; Perrone G; Ceccolini M; Baccarani M; Cavo M. | 2006-01-01 | ANNALS OF HEMATOLOGY | - | 1.01 Articolo in rivista | - |
| Prediction of response to primary therapy with thalidomide-dexamethasone (thal-dex) for newly diagnosed multiple myeloma by gene expression profiling (gep) | Terragna, C.; Renzulli, M.; Remondini, D.; Tagliafico, E.; Roncaglia, E.; Tosi, P.; Zamagni, E.; ...Tacchetti, P.; Perrone, G.; Ceccolini, M.; Brioli, Am.; Martinelli, G.; Baccarani, M.; Cavo, M. | 2007-01-01 | - | - | 4.02 Riassunto (Abstract) | - |
| Neuropathy in multiple myeloma treated with thalidomide: a prospective study. | Plasmati R; Pastorelli F; Cavo M; Petracci E; Zamagni E; Tosi P; Cangini D; Tacchetti P; Salvi F;... Bartolomei I; Michelucci R; Tassinari CA. | 2007-01-01 | NEUROLOGY | - | 1.01 Articolo in rivista | - |
| Prediction of response to primary therapy with thalidomide-dexamethasone (thal-dex) for newly diagnosed multiple myeloma by gene expression profiling (gep) | Terragna C.; Renzulli M.; Remondini D.; Tagliafico E.; Roncaglia E.; Tosi P.; Zamagni E.; Tacchet...ti P.; Perrone G.; Ceccolini M.; Brioli AM.; Martinelli G.; Baccarani M.; Cavo M. | 2007-01-01 | HAEMATOLOGICA | - | 4.02 Riassunto (Abstract) | - |
| Gene expression profiling (gep) of myeloma (MM) cells to predict attainment near complete response to primary therapy with thalidomide-dexamethasone (thal-dex) for newly diagnosed MM | C. Terragna; M. Renzulli; D. Remondini; E. Tagliafico; E. Roncaglia; P. Tosi; E. Zamagni; P. Tacc...hetti; G. Perrone; M. Ceccolini; G. Martinelli; M. Baccarani; M. Cavo | 2007-01-01 | BLOOD | - | 4.02 Riassunto (Abstract) | - |
| Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study. | Cavo M; Tosi P; Zamagni E; Cellini C; Tacchetti P; Patriarca F; Di Raimondo F; Volpe E; Ronconi S...; Cangini D; Narni F; Carubelli A; Masini L; Catalano L; Fiacchini M; de Vivo A; Gozzetti A; Lazzaro A; Tura S; Baccarani M. | 2007-01-01 | JOURNAL OF CLINICAL ONCOLOGY | - | 1.01 Articolo in rivista | - |
| A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma. | Zamagni E; Nanni C; Patriarca F; Englaro E; Castellucci P; Geatti O; Tosi P; Tacchetti P; Cangini... D; Perrone G; Ceccolini M; Brioli A; Buttignol S; Fanin R; Salizzoni E; Baccarani M; Fanti S; Cavo M. | 2007-01-01 | HAEMATOLOGICA | - | 1.01 Articolo in rivista | - |
| 11C-choline vs. 18F-FDG PET/CT in assessing bone involvement in patients with multiple myeloma. | Nanni C; Zamagni E; Cavo M; Rubello D; Tacchetti P; Pettinato C; Farsad M; Castellucci P; Ambrosi...ni V; Montini GC; Al-Nahhas A; Franchi R; Fanti S. | 2007-01-01 | WORLD JOURNAL OF SURGICAL ONCOLOGY | - | 1.01 Articolo in rivista | - |
| Evaluation of bone disease in multiple myeloma patients carrying the t(4;14) chromosomal translocation. | Tosi P; Terragna C; Testoni N; Zamagni E; Renzulli M; Tacchetti P; Montanari E; Perrone G; Ceccol...ini M; Brioli A; Pallotti MC; Tura S; Baccarani M; Cavo M. | 2008-01-01 | EUROPEAN JOURNAL OF HAEMATOLOGY | - | 1.01 Articolo in rivista | - |
| Proteasome inhibitors: Bortezomib in multiple myeloma | Cavo M.; Pallotti M.C.; Pantani L.; Petrucci A.; Brioli A.; Terragna C.; Testoni N.; Marzocchi G....; Durante S.; Ceccolini M.; Perrone G.; Tacchetti P.; Zamagni E.; Tosi P.; Baccarani M. | 2008-01-01 | HEMATOLOGY MEETING REPORTS | - | 1.01 Articolo in rivista | - |
| Short-term thalidomide incorporated into double autologous stem-cell transplantation improves outcomes in comparison with double autotransplantation for multiple myeloma. | Cavo M; Di Raimondo F; Zamagni E; Patriarca F; Tacchetti P; Casulli AF; Volpe S; Perrone G; Ledda... A; Ceccolini M; Califano C; Bigazzi C; Offidani M; Stefani P; Ballerini F; Fiacchini M; de Vivo A; Brioli A; Tosi P; Baccarani M. | 2009-01-01 | JOURNAL OF CLINICAL ONCOLOGY | - | 1.01 Articolo in rivista | - |
| Thalidomide maintenance in multiple myeloma: certainties and controversies. | Cavo M; Pantani L; Tacchetti P; Pallotti MC; Brioli A; Petrucci A; Zamagni E; Tosi P. | 2009-01-01 | JOURNAL OF CLINICAL ONCOLOGY | - | 1.04 Replica / breve intervento (e simili) | - |
| The road to cure in multiple myeloma: Incorporation of novel agents into autologous stem cell transplantation | Cavo M.; Zamagni E.; Tacchetti P.; Brioli A.; Pallotti C.; Pantani L.; Ceccolini M.; Petrucci A.;... Testoni N.; Terragna C.; Marzocchi G.; Durante S.; Tosi P.; Baccarani M. | 2009-01-01 | HEMATOLOGY MEETING REPORTS | - | 1.01 Articolo in rivista | - |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile